|Original language||English (US)|
|Number of pages||2|
|State||Published - Aug 1 2021|
Bibliographical noteFunding Information:
personal fees from Sarepta Therapeutics (advisory board) and Novartis/AveXis (consultant) and grant funding from ML Bio Solutions outside the submitted work. No other disclosures were reported.
PubMed: MeSH publication types